Inventor · disambiguated record
Gregory R. Ott
Also filed as: OTT GREGORY · OTT GREGORY R
27 granted patents·10 pending applications·138 citations·filing 2001–2025
95Inventor score
Files withCEPHALON INC12CANCER RESEARCH TECH LTD6BRISTOL MYERS SQUIBB PHARMA CO3CENTESSA PHARMACEUTICALS UK LTD3NXERA PHARMA UK LTD3
Top patents by PatentIndex Score
37 records- 0189US11766434B2Pyrimidinone derivatives as CDC7 inhibitorsCANCER RESEARCH TECH LTD·Filed 2021·Granted Sep 26, 2023·2 cites·19 claims
- 0289US8148391B2Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitorsAHMED GULZAR·Filed 2007·Granted Apr 3, 2012·17 cites·8 claims
- 0387US9604994B2Thienopyrimidine inhibitors of atypical protein kinase CCANCER RES TECH LTD·Filed 2014·Granted Mar 28, 2017·12 cites·26 claims
- 0487US9339502B2Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitorCEPHALON INC·Filed 2015·Granted May 17, 2016·5 cites·21 claims
- 0587US9132128B2Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitorCEPHALON INC·Filed 2014·Granted Sep 15, 2015·7 cites·20 claims
- 0687US6740649B2Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)BRISTOL MYERS SQUIBB CO·Filed 2002·Granted May 25, 2004·31 cites·49 claims
- 0786US9623026B2Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitorCEPHALON INC·Filed 2016·Granted Apr 18, 2017·4 cites·10 claims
- 0885US8552186B2Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitorsAHMED GULZAR·Filed 2012·Granted Oct 8, 2013·10 cites·26 claims
- 0982US9914730B2Azaquinazoline inhibitors of Atypical protein Kinase CIGNYTA INC·Filed 2013·Granted Mar 13, 2018·6 cites·13 claims
- 1082US9896446B2Azaquinazoline inhibitors of atypical protein kinase CIGNYTA INC·Filed 2015·Granted Feb 20, 2018·4 cites·14 claims
- 1182US6984648B2Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-αBRISTOL MYERS SQUIBB PHARMA CO·Filed 2004·Granted Jan 10, 2006·15 cites·21 claims
- 1282US6743807B2Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-αBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Jun 1, 2004·15 cites·42 claims
- 1381US10111872B2Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitorCEPHALON INC·Filed 2017·Granted Oct 30, 2018·2 cites·21 claims
- 1478US11020396B2Pyrimidinone derivatives as Cdc7 inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Jun 1, 2021·2 cites·20 claims
- 1576US2025136616A1Cgrp antagonist compoundsNXERA PHARMA UK LTD·Filed 2024·Application pending·0 cites
- 1674US9487529B2Macrocyclic compounds as ALK, FAK and JAK2 inhibitorsCEPHALON INC·Filed 2013·Granted Nov 8, 2016·1 cites·22 claims
- 1774US2025236629A1Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related usesCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 1873US8471005B2Pyrrolotriazines as ALK and JAK2 inhibitorsBRESLIN HENRY J·Filed 2011·Granted Jun 25, 2013·3 cites·10 claims
- 1971US9238656B2Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disordersCEPHALON INC·Filed 2014·Granted Jan 19, 2016·1 cites·28 claims
- 2069US10632119B2Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitorCEPHALON INC·Filed 2018·Granted Apr 28, 2020·0 cites·21 claims
- 2167US2025100968A1Bicyclic-heterocycle derivatives and related usesCENTESSA PHARMACEUTICALS UK LTD·Filed 2024·Application pending·0 cites
- 2264US12227521B2CGRP antagonist compoundsNXERA PHARMA UK LTD·Filed 2020·Granted Feb 18, 2025·0 cites·31 claims
- 2364US10954251B2Thienopyrimidine inhibitors of atypical protein kinase CCANCER RESEARCH TECH LTD·Filed 2018·Granted Mar 23, 2021·0 cites·19 claims
- 2463US2025289828A1Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related usesCENTESSA PHARMACEUTICALS UK LTD·Filed 2025·Application pending·0 cites
- 2562US6720329B2Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB PHARMA·Filed 2002·Granted Apr 13, 2004·1 cites·28 claims
- 2659US2019308934A1Prodrugs of ChlorokynureninesCEPHALON INC·Filed 2019·Application pending·0 cites
- 2758US9440984B2Pyrrolotriazines as ALK inhibitorsCEPHALON INC·Filed 2015·Granted Sep 13, 2016·0 cites·20 claims
- 2855US10183950B2Thienopyrimidine inhibitors of atypical protein kinase CCANCER RESEARCH TECH LTD·Filed 2017·Granted Jan 22, 2019·0 cites·10 claims
- 2955US2017027948A1Macrocyclic compounds as alk, fak and jak2 inhibitorsCEPHALON INC·Filed 2016·Application pending·0 cites
- 3053US12344621B2CGRP antagonist compoundsNXERA PHARMA UK LTD·Filed 2020·Granted Jul 1, 2025·0 cites·31 claims
- 3152US6962938B2Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)BRISTOL MYERS SQUIBB PHARMA CO·Filed 2003·Granted Nov 8, 2005·0 cites·19 claims
- 3251US2018327351A1Prodrugs of chlorokynureninesCEPHALON INC·Filed 2016·Application pending·0 cites
- 3350US2016347756A1Pyrrolotriazines as alk inhibitorsCEPHALON INC·Filed 2016·Application pending·0 cites
- 3443US2018305298A1Deuterated chlorokynurenines for the treatment of neuropsychiatric disordersAUSPEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3541US2003212056A1Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)Filed 2002·Application pending·0 cites
- 3633US10919896B2Preparation and uses of pyrimidinone derivativesCANCER RESEARCH TECH LTD·Filed 2017·Granted Feb 16, 2021·0 cites·17 claims
- 3732US10414763B2Azaquinazoline inhibitors of atypical protein kinase CCANCER RESEARCH TECH LTD·Filed 2015·Granted Sep 17, 2019·0 cites·29 claims
Join the waitlist — get patent alerts
Get an alert when Gregory R. Ott files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →